Physician profile
Lisa Dewitt
NPI 1093472953
$10,531.24
in general payments reported to CMS, 2019-2025
30 companies · $3,225 in 2025
The $3,225 reported for 2025 was more than what 97% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $276 · 2022: $1,319 · 2023: $2,751 · 2024: $2,960 · 2025: $3,225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,799 · Education: $137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,798.97 |
| Education | $136.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,689.95 | 2022-2025 | |
| Alkermes, INC. | $1,287.71 | 2021-2025 | Lybalvi, Aristada, Aristada Initio |
| Teva Pharmaceuticals USA, INC. | $1,238.32 | 2022-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $846.19 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Lundbeck LLC | $583.90 | 2022-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $579.81 | 2022-2025 | Invega Sustenna, Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $506.55 | 2023-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $499.36 | 2023-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $498.87 | 2022-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $437.62 | 2021-2025 | Ingrezza |
| Idorsia Pharmaceuticals US INC | $346.66 | 2023-2024 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $327.65 | 2022-2025 | Trintellix |
| Corium, LLC | $308.26 | 2022-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $288.69 | 2023-2025 | Qelbree, Qelbree |
| Avanir Pharmaceuticals, INC. | $134.51 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $114.03 | 2023-2025 | Dyanavel Xr |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $112.43 | 2022-2025 | |
| Sage Therapeutics, LLC | $94.02 | 2025 | Zurzuvae |
| Ironshore Pharmaceuticals INC. | $89.58 | 2022-2024 | Jornay Pm |
| E.R. Squibb & Sons, L.L.C. | $70.48 | 2024-2025 | Cobenfy |
| Acadia Pharmaceuticals INC | $66.22 | 2022-2025 | Nuplazid |
| Noven Therapeutics, LLC | $63.71 | 2022-2024 | Xelstrym, Secuado |
| Almatica Pharma LLC | $62.32 | 2022-2025 | Loreev Xr |
| Neos Therapeutics, Lp | $55.04 | 2022-2023 | Adzenys Xr-Odt |
| Tempus Ai, INC | $49.84 | 2024 | |
| Sunovion Pharmaceuticals INC. | $49.63 | 2022 | |
| Azurity Pharmaceuticals, INC. | $45.88 | 2023 | Horizant |
| Indivior INC. | $34.98 | 2023-2024 | Perseris |
| Avion Pharmaceuticals | $32.83 | 2023 | Methylphenidate Hydrochloride |
| Collegium Pharmaceutical, INC. | $16.20 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Dewitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.